Egg-Free Universal Flu Vaccine for Robust, Long-Lasting Immunity

Description

This technology is a nanoparticle-based influenza vaccine that provides broad and durable protection against both influenza A and B viruses. It elicits strong, long-lasting adaptive immunity and fully protects vaccinated animals from a wide range of influenza A strains, without the use of adjuvants. Designed for versatility, the vaccine can potentially be delivered via injection, nasal spray or drops, or self-administered microneedle patches.

More than 3 million cases of influenza are reported in the US alone each year, resulting in high mortality and morbidity. Annual influenza infections are caused by either of two types of viruses, influenza A or influenza B.  Current seasonal influenza vaccines remain suboptimal due to the need to preselect vaccine strains, antigenic drift, and time-consuming culture systems.

Benefits

• Long-lasting Immunity: Vaccinated animals are fully protected against divergent influenza A infections
• Adjuvant-Free Administration: Without adjuvant, this construct may reduce inflammation caused by injection as well as other side effects
• Egg-Free: Improved efficacy without worrying about potential mutations at critical locations on the virus
• Adaptable Design: This construct can be incorporated into or replace the currently marketed seasonal influenza A vaccines, and supplement other existing human vaccines.
• Simple Manufacturing and Faster Production: Simplifies production and shortens timelines, allowing a faster response to emerging strains and supporting annual vaccine demands.

Applications

• Universal Influenza Vaccine

Patent Status

• https://patents.google.com/patent/WO2019070955A1/en?oq=https:%2f%2fpatentscope.wipo.int%2fsearch%2fen%2fdetail.jsf%3fdocId%3dWO2019070955

Publications

Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses